Verenigde Staten - Engels - NLM (National Library of Medicine)

patterson veterinary - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz), phytosphingosine hydrochloride (unii: tt871xv7tu) (phytosphingosine - unii:gin46u9q2q) - salicylic acid 1.5 mg in 1 ml - indication: for use on dogs and cats only. for cleansing and/or drying the ear canal. directions for use:  apply liberally into the ear canal. massage the base of the ear. allow pet to shake head. clean excess with a cotton ball. in excessively dirty ears, apply 2-3 times daily over several days. for maintenance of healthy ears, apply 1-2 times weekly or as directed by your veterinarian. recommended after swimming to help dry ear canal.

Verenigde Staten - Engels - NLM (National Library of Medicine)

mylan institutional llc - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5)] . zoledronic acid is contraindicated in patients with the following conditions: in female rats given daily subcutaneous doses of 0.01, 0.03, or 0.1 mg/kg, beginning 15 days before mating and continuing through gestation, parturition and lactation, dystocia and periparturient mortality were observed in pregnant rats allowed to deliver starting at 0.01 mg/kg/day (0.1 times the human 5 mg intravenous dose, based on auc). also, there was an increase in stillbirths and a decrease in neonate survival starting at 0.03 mg/kg/day (0.3 times the human 5 mg dose), while the number of viable newborns and pup body weig

Verenigde Staten - Engels - NLM (National Library of Medicine)

mylan institutional inc. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk due to their age (≥ 60) and/or d

Verenigde Staten - Engels - NLM (National Library of Medicine)

par pharmaceutical - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid oral solution is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1)   for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless th

Malta - Engels - Medicines Authority

medicem limited 57a ta’ maggi industrial estate, st. leonard street, xghajra l/o zabbar, zbr 2305, malta - salicylic acid, lactic acid - solution - salicylic acid 16.7 % (w/w) lactic acid 15 % (w/w) - stomatological preparations

Ierland - Engels - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - refined olive oil + refined soybean oil; alanine; arginine ; aspartic acid; glutamic acid ; glycine; histidine; isoleucine; leucine ; lysine; methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine; valine; glucose monohydrate - emulsion for infusion - 7g/l/1140kcal/l - solutions for parenteral nutrition; combinations

Ierland - Engels - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - refined olive oil + refined soybean oil; alanine; arginine ; aspartic acid; glutamic acid ; glycine; histidine; isoleucine; leucine ; lysine; methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine; valine; glucose monohydrate; sodium acetate (as trihydrate); sodium glycerophosphate, hydrated; potassium chloride; magnesium chloride hexahydrate; calcium chloride dihydrate - emulsion for infusion - 7g/l / 1140kcal/l - solutions for parenteral nutrition; combinations

Verenigde Staten - Engels - NLM (National Library of Medicine)

sandoz inc - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide acetate is indicated to reduce blood levels of growth hormone and igf-i (somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of growth hormone and igf-i (somatomedin c) levels (see dosage and administration ). in patients with acromegaly, octreotide acetate reduces growth hormone to within normal ranges in 50% of patients and reduces igf-i (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate to reduce blood levels of growth hormone and igf-i (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide a

Verenigde Staten - Engels - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole delayed-release orally disintegrating tablets are indicated for in adults short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14.1)] . triple therapy: lansoprazole delayed-release orally disintegrating tablets /amoxicillin/clarithromycin lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.2)]   please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole delayed-release orally disintegrating tablets/amoxicillin lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin as dual therapy

Malta - Engels - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - salicylic acid, lactic acid - cutaneous solution - salicylic acid 16.7 % (w/w) lactic acid 15 % (w/w) - other dermatological preparations